We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Can Coronavirus Vaccine Efforts Aid Novavax (NVAX) Q3 Earnings?
Read MoreHide Full Article
We expect investors to focus on Novavax, Inc.’s (NVAX - Free Report) development efforts for its coronavirus vaccine candidate NVX-CoV2373 when it reports third-quarter 2020 earnings results.
The company’s surprise record has been mixed so far as its bottom line beat estimates in two of the trailing four quarters and lagged the same on the other two occasions, the average beat being 13.80%. In the last reported quarter, Novavax witnessed an earnings surprise of 47.37%.
Shares of Novavax have skyrocketed 2151% in the year so far against the industry’s 4.9% decrease.
Let’s see how things have shaped up for this announcement.
Key Factors to Note
Novavax’s portfolio is currently devoid of any approved product. As a result, the company is yet to generate any revenues from its product sales.
On the third-quarter earnings call, investors’ will likely keep tabs on the progress of Novavax’s pipeline of vaccine candidates, especially the coronavirus vaccine.
The company has been actively engaged in developing its coronavirus vaccine NVX-CoV2373. In September 2020, Novavax initiated the first phase III study evaluating the safety, efficacy and immunogenicity of NVX-CoV2373 in the United Kingdom. The study is being conducted in partnership with the UK Government’s Vaccines Taskforce and is expected to enroll over the next four to six weeks around 10,000 individuals aged between 18 years and 84 years regardless of any relevant co-morbidity.
However, earlier this week, Novavax announced that above study expanded to 15,000 volunteers, having already enrolled more than 5,500 participants to date. Interim data from the same is expected in the first quarter of 2021.
Meanwhile, the phase III study of NVX-CoV2373 in the United States and Mexico is expected to begin by the end of November. This study is being conducted under the U.S. government’s Operation Warp Speed (OWS). An update on the timeline of these studies is expected during the third-quarter conference call.
The study and development activities related to NVX-CoV2373 are likely to have escalated the operating expense in the to-be-reported quarter.
Novavax already received a $2-billion funding for developing NVX-CoV2373.
Meanwhile, Novavax has been extending its global manufacturing capacities through significant collaborations or acquisitions of companies, thereby providing contract development and manufacturing services to manufacture NVX-CoV2373.
We note that the company successfully completed a phase III study on its lead vaccine candidate NanoFlu, which it evaluated for seasonal influenza earlier this year. The candidate was found non-inferior to Sanofi’s (SNY - Free Report) influenza vaccine Fluzone.
Novavax will file a biologics license application (BLA) to the FDA shortly, seeking an accelerated approval for NanoFlu. The activities related to filing a BLA might have shot up the company’s operating expenses. An update on the regulatory timeline of the vaccine is expected during the upcoming investors’ call.
Earnings Whispers
Our proven model does not conclusively predict an earnings beat for Novavax this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. But that is not the case here.
Earnings ESP: Novavax has an Earnings ESP of 0.00% as both the Zacks Consensus Estimate and the Most Accurate Estimate stand at $2.36 per share. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Zacks Rank: Novavax currently carries a Zacks Rank #4 (Sell).
Here are some drug/biotech stocks worth considering from the same space as our model shows that these have the right combination of elements to beat on earnings this reporting cycle.
Vertex Pharmaceuticals Incorporated (VRTX - Free Report) has an Earnings ESP of +3.83% and a Zacks Rank of 3, presently. The company is scheduled to report earnings on Oct 29.
Zacks’ 2020 Election Stock Report:
In addition to the companies you learned about above, we invite you to learn more about profiting from the upcoming presidential election. Trillions of dollars will shift into new market sectors after the votes are tallied, and investors could see significant gains. This report reveals specific stocks that could soar: 6 if Trump wins, 6 if Biden wins.
Image: Shutterstock
Can Coronavirus Vaccine Efforts Aid Novavax (NVAX) Q3 Earnings?
We expect investors to focus on Novavax, Inc.’s (NVAX - Free Report) development efforts for its coronavirus vaccine candidate NVX-CoV2373 when it reports third-quarter 2020 earnings results.
The company’s surprise record has been mixed so far as its bottom line beat estimates in two of the trailing four quarters and lagged the same on the other two occasions, the average beat being 13.80%. In the last reported quarter, Novavax witnessed an earnings surprise of 47.37%.
Shares of Novavax have skyrocketed 2151% in the year so far against the industry’s 4.9% decrease.
Let’s see how things have shaped up for this announcement.
Key Factors to Note
Novavax’s portfolio is currently devoid of any approved product. As a result, the company is yet to generate any revenues from its product sales.
On the third-quarter earnings call, investors’ will likely keep tabs on the progress of Novavax’s pipeline of vaccine candidates, especially the coronavirus vaccine.
The company has been actively engaged in developing its coronavirus vaccine NVX-CoV2373. In September 2020, Novavax initiated the first phase III study evaluating the safety, efficacy and immunogenicity of NVX-CoV2373 in the United Kingdom. The study is being conducted in partnership with the UK Government’s Vaccines Taskforce and is expected to enroll over the next four to six weeks around 10,000 individuals aged between 18 years and 84 years regardless of any relevant co-morbidity.
However, earlier this week, Novavax announced that above study expanded to 15,000 volunteers, having already enrolled more than 5,500 participants to date. Interim data from the same is expected in the first quarter of 2021.
Meanwhile, the phase III study of NVX-CoV2373 in the United States and Mexico is expected to begin by the end of November. This study is being conducted under the U.S. government’s Operation Warp Speed (OWS). An update on the timeline of these studies is expected during the third-quarter conference call.
The study and development activities related to NVX-CoV2373 are likely to have escalated the operating expense in the to-be-reported quarter.
Novavax already received a $2-billion funding for developing NVX-CoV2373.
Meanwhile, Novavax has been extending its global manufacturing capacities through significant collaborations or acquisitions of companies, thereby providing contract development and manufacturing services to manufacture NVX-CoV2373.
We note that the company successfully completed a phase III study on its lead vaccine candidate NanoFlu, which it evaluated for seasonal influenza earlier this year. The candidate was found non-inferior to Sanofi’s (SNY - Free Report) influenza vaccine Fluzone.
Novavax will file a biologics license application (BLA) to the FDA shortly, seeking an accelerated approval for NanoFlu. The activities related to filing a BLA might have shot up the company’s operating expenses. An update on the regulatory timeline of the vaccine is expected during the upcoming investors’ call.
Earnings Whispers
Our proven model does not conclusively predict an earnings beat for Novavax this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. But that is not the case here.
Earnings ESP: Novavax has an Earnings ESP of 0.00% as both the Zacks Consensus Estimate and the Most Accurate Estimate stand at $2.36 per share. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Zacks Rank: Novavax currently carries a Zacks Rank #4 (Sell).
Novavax, Inc. Price and Consensus
Novavax, Inc. price-consensus-chart | Novavax, Inc. Quote
Stocks to Consider
Here are some drug/biotech stocks worth considering from the same space as our model shows that these have the right combination of elements to beat on earnings this reporting cycle.
Alnylam Pharmaceuticals (ALNY - Free Report) has an Earnings ESP of +4.23% and a Zacks Rank #3, currently. The company is scheduled to report earnings on Nov 5. You can see the complete list of today’s Zacks #1 Rank stocks here.
Vertex Pharmaceuticals Incorporated (VRTX - Free Report) has an Earnings ESP of +3.83% and a Zacks Rank of 3, presently. The company is scheduled to report earnings on Oct 29.
Zacks’ 2020 Election Stock Report:
In addition to the companies you learned about above, we invite you to learn more about profiting from the upcoming presidential election. Trillions of dollars will shift into new market sectors after the votes are tallied, and investors could see significant gains. This report reveals specific stocks that could soar: 6 if Trump wins, 6 if Biden wins.
Check out the 2020 Election Stock Report >>